Publications scientifiques en 2017

Depuis le 31/03/2025

  1. News from Tartary: an ethnopharmacological approach to drug and therapeutic discovery.
    Moore N, Hamza N, Berke B, Umar A.
    Br J Clin Pharmacol. 2017
  2. Impact of a public media event on the use of statins in the French population.
    Bezin J, Francis F, Nguyen NV, Robinson P, Blin P, Fourrier-Réglat A, Pariente A, Moore N.
    Arch Cardiovasc Dis. 2017
  3. Pharmacological treatments of cardiovascular diseases: Evidence from real-life studies.
    Salvo F, Bezin J, Bosco-Levy P, Letinier L, Blin P, Pariente A, Moore N.
    Pharmacol Res. 2017
  4. Parachuting: a dangerous trend in recreational psychoactive substance delivery.
    Boels D, Grall-Bronnec M, Guerlais M, Le Roux G, Spiers A, Gerardin M, Lomenech H, Bretaudeau-Deguigne M, Daveluy A, Turcant A, Jolliet P, Victorri-Vigneau C.
    Expert Opin Drug Deliv. 2017
  5. Which psychoactive substances are used by patients seen in the healthcare system in French overseas territories? Results of the OPPIDUM survey.
    Daveluy A, Frauger E, Peyrière H, Moracchini C, Haramburu F, Micallef J.
    Fundam Clin Pharmacol. 2017
  6. How are elderly patients treated after a diagnosis of metastatic colorectal cancer in real-life practice? A study in a French teaching hospital.
    Gouverneur A, Rouyer M, Grelaud A, Robinson P, Colombani F, Terrebonne E, Smith D, Fourrier-Réglat A, Noize P.
    Fundam Clin Pharmacol. 2017
  7. An original pharmacoepidemiological-pharmacodynamic method: application to antipsychotic-induced movement disorders.
    Nguyen TT, Pariente A, Montastruc JL, Lapeyre-Mestre M, Rousseau V, Rascol O, Bégaud B, Montastruc F.
    Br J Clin Pharmacol. 2017
  8. Late diagnosis of primary hyperoxaluria type III.
    Richard E, Blouin JM, Harambat J, Llanas B, Bouchet S, Acquaviva C, de la Faille R.
    Ann Clin Biochem. 2017
  9. Trends in incident use of benzodiazepines and Z-drugs in France from 2006 to 2012: a population-based study.
    Bénard-Laribière A, Noize P, Pambrun E, Bazin F, Verdoux H, Tournier M, Bégaud B, Pariente A.
    Pharmacoepidemiol Drug Saf. 2017
  10. Risk of Myopathy Associated With DPP-4 Inhibitors in Combination With Statins: A Disproportionality Analysis Using Data From the WHO and French Spontaneous Reporting Databases.
    Labat V, Arnaud M, Miremont-Salamé G, Salvo F, Bégaud B, Pariente A.
    Diabetes Care. 2017
  11. Evidence for the hERG Liability of Antihistamines, Antipsychotics, and Anti-Infective Agents: A Systematic Literature Review From the ARITMO Project.
    Hazell L, Raschi E, De Ponti F, Thomas SH, Salvo F, Ahlberg Helgee E, Boyer S, Sturkenboom M, Shakir S.
    J Clin Pharmacol. 2017
  12. Comparative effectiveness of recommended versus less intensive drug combinations in secondary prevention of acute coronary syndrome.
    Bezin J, Groenwold RH, Ali MS, Lassalle R, Robinson P, de Boer A, Moore N, Klungel OH, Pariente A.
    Pharmacoepidemiol Drug Saf. 2017
  13. [Costs of healthcare resource consumption after a myocardial infarction in France: An estimate from a medicoadministrative database (GSB)]
    Philippe F, Blin P, Bouée S, Laurendeau C, Torreton E, Gourmelin J, Velkovski-Rouyer M, Levy-Bachelot L, Steg G.
    Ann Cardiol Angeiol (Paris). 2017
  14. Chronic obstructive pulmonary disease exacerbation and inhaler device handling: real-life assessment of 2935 patients.
    Molimard M, Raherison C, Lignot S, Balestra A, Lamarque S, Chartier A, Droz-Perroteau C, Lassalle R, Moore N, Girodet PO.
    Eur Respir J. 2017
  15. Erratum to: Scaling up strategies of the chronic respiratory disease programme of the European Innovation Partnership on Active and Healthy Ageing (Action Plan B3: Area 5).
    Bousquet J, Farrell J, Crooks G, Hellings P, Bel EH, Bewick M, Chavannes NH, de Sousa JC, Cruz AA, Haahtela T, Joos G, Khaltaev N, Malva J, Muraro A, Nogues M, Palkonen S, Pedersen S, Robalo-Cordeiro C, Samolinski B, Strandberg T, Valiulis A, Yorgancioglu A, Zuberbier T, Bedbrook A, Aberer W, Adachi M, Agusti A, Akdis CA, Akdis M, Ankri J, Alonso A, Annesi-Maesano I, Ansotegui IJ, Anto JM, Arnavielhe S, Arshad H, Bai C, Baiardini I, Bachert C, Baigenzhin AK, Barbara C, Bateman ED, Beghé B, Kheder AB, Bennoor KS, Benson M, Bergmann KC, Bieber T, Bindslev-Jensen C, Bjermer L, Blain H, Blasi F, Boner AL, Bonini M, Bonini S, Bosnic-Anticevitch S, Boulet LP, Bourret R, Bousquet PJ, Braido F, Briggs AH, Brightling CE, Brozek J, Buhl R, Burney PG, Bush A, Caballero-Fonseca F, Caimmi D, Calderon MA, Calverley PM, Camargos PA, Canonica GW, Camuzat T, Carlsen KH, Carr W, Carriazo A, Casale T, Cepeda Sarabia AM, Chatzi L, Chen YZ, Chiron R, Chkhartishvili E, Chuchalin AG, Chung KF, Ciprandi G, Cirule I, Cox L, Costa DJ, Custovic A, Dahl R, Dahlen SE, Darsow U, De Carlo G, De Blay F, Dedeu T, Deleanu D, De Manuel Keenoy E, Demoly P, Denburg JA, Devillier P, Didier A, Dinh-Xuan AT, Djukanovic R, Dokic D, Douagui H, Dray G, Dubakiene R, Durham SR, Dykewicz MS, El-Gamal Y, Emuzyte R, Fabbri LM, Fletcher M, Fiocchi A, Fink Wagner A, Fonseca J, Fokkens WJ, Forastiere F, Frith P, Gaga M, Gamkrelidze A, Garces J, Garcia-Aymerich J, Gemicio?lu B, Gereda JE, González Diaz S, Gotua M, Grisle I, Grouse L, Gutter Z, Guzmán MA, Heaney LG, Hellquist-Dahl B, Henderson D, Hendry A, Heinrich J, Heve D, Horak F, Hourihane JO, Howarth P, Humbert M, Hyland ME, Illario M, Ivancevich JC, Jardim JR, Jares EJ, Jeandel C, Jenkins C, Johnston SL, Jonquet O, Julge K, Jung KS, Just J, Kaidashev I, Khaitov MR, Kalayci O, Kalyoncu AF, Keil T, Keith PK, Klimek L, Koffi N'Goran B, Kolek V, Koppelman GH, Kowalski ML, Kull I, Kuna P, Kvedariene V, Lambrecht B, Lau S, Larenas-Linnemann D, Laune D, Le LT, Lieberman P, Lipworth B, Li J, Lodrup Carlsen K, Louis R, MacNee W, Magard Y, Magnan A, Mahboub B, Mair A, Majer I, Makela MJ, Manning P, Mara S, Marshall GD, Masjedi MR, Matignon P, Maurer M, Mavale-Manuel S, Melén E, Melo-Gomes E, Meltzer EO, Menzies-Gow A, Merk H, Michel JP, Miculinic N, Mihaltan F, Milenkovic B, Mohammad GM, Molimard M, Momas I, Montilla-Santana A, Morais-Almeida M, Morgan M, Mösges R, Mullol J, Nafti S, Namazova-Baranova L, Naclerio R, Neou A, Neffen H, Nekam K, Niggemann B, Ninot G, Nyembue TD, O'Hehir RE, Ohta K, Okamoto Y, Okubo K, Ouedraogo S, Paggiaro P, Pali-Schöll I, Panzner P, Papadopoulos N, Papi A, Park HS, Passalacqua G, Pavord I, Pawankar R, Pengelly R, Pfaar O, Picard R, Pigearias B, Pin I, Plavec D, Poethig D, Pohl W, Popov TA, Portejoie F, Potter P, Postma D, Price D, Rabe KF, Raciborski F, Radier Pontal F, Repka-Ramirez S, Reitamo S, Rennard S, Rodenas F, Roberts J, Roca J, Rodriguez Mañas L, Rolland C, Roman Rodriguez M, Romano A, Rosado-Pinto J, Rosario N, Rosenwasser L, Rottem M, Ryan D, Sanchez-Borges M, Scadding GK, Schunemann HJ, Serrano E, Schmid-Grendelmeier P, Schulz H, Sheikh A, Shields M, Siafakas N, Sibille Y, Similowski T, Simons FE, Sisul JC, Skrindo I, Smit HA, Solé D, Sooronbaev T, Spranger O, Stelmach R, Sterk PJ, Sunyer J, Thijs C, To T, Todo-Bom A, Triggiani M, Valenta R, Valero AL, Valia E, Valovirta E, Van Ganse E, van Hage M, Vandenplas O, Vasankari T, Vellas B, Vestbo J, Vezzani G, Vichyanond P, Viegi G, Vogelmeier C, Vontetsianos T, Wagenmann M, Wallaert B, Walker S, Wang DY, Wahn U, Wickman M, Williams DM, Williams S, Wright J, Yawn BP, Yiallouros PK, Yusuf OM, Zaidi A, Zar HJ, Zernotti ME, Zhang L, Zhong N, Zidarn M, Mercier J.
    Clin Transl Allergy. 2017
  16. Scientific Rationale for Determining the Bioequivalence of Inhaled Drugs .
    Usmani OS, Molimard M, Gaur V, Gogtay J, Singh GJ, Malhotra G, Derom E.
    Clin Pharmacokinet. 2017
  17. Identifying atrial fibrillation in outpatients initiating oral anticoagulants based on medico-administrative data: results from the French national healthcare databases.
    Billionnet C, Alla F, Bérigaud É, Pariente A, Maura G.
    Pharmacoepidemiol Drug Saf. 2017
  18. Risk of discontinuation of antipsychotic long-acting injections vs. oral antipsychotics in real-life prescribing practice: a community-based study.
    Verdoux H, Pambrun E, Tournier M, Bezin J, Pariente A.
    Acta Psychiatr Scand. 2017
  19. Type 2 Diabetes Mellitus Treatment Patterns Across Europe: A Population-Based Multi-Database Study.
    Overbeek JA, Heintjes EM, Prieto-Alhambra D, Blin P, Lassalle R, Hall GC, Lapi F, Bianchini E, Hammar N, Bezemer ID, Herings RM.
    Clin Ther. 2017
  20. [Surveillance system on drug abuse: Interest of the French national OPPIDUM program of French addictovigilance network]
    Frauger E, Pochard L, Boucherie Q, Giocanti A, Chevallier C, Daveluy A, Gibaja V, Caous AS, Eiden C, Authier N, Le Boisselier R, Guerlais M, Jouanjus É, Lepelley M, Pizzoglio V, Pain S, Richard N, Micallef J; le Réseau français d’addictovigilance.
    Therapie. 2017
  21. Outcomes in patients after myocardial infarction similar to those of the PEGASUS-TIMI 54 trial: A cohort study in the French national claims database.
    Blin P, Dureau-Pournin C, Lassalle R, Jové J, Thomas-Delecourt F, Droz-Perroteau C, Danchin N, Moore N.
    Br J Clin Pharmacol. 2017
  22. A multinational, drug utilization study to investigate the use of dexmedetomidine (Dexdor®) in clinical practice in the EU.
    Weatherall M, Aantaa R, Conti G, Garratt C, Pohjanjousi P, Lewis MA, Moore N, Perez-Gutthann S.
    Br J Clin Pharmacol. 2017
  23. Potential Limitations of a very short course of antimicrobial therapy for VAP.
    Boyer A, Leffondre K, Laterrade T, Berdaï D, Gruson D.
    Clin Infect Dis. 2017
  24. An UPLC-MS/MS method for the quantification of BRAF inhibitors (vemurafenib, dabrafenib) and MEK inhibitors (cobimetinib, trametinib, binimetinib) in human plasma. Application to treated melanoma patients.
    Rousset M, Titier K, Bouchet S, Dutriaux C, Pham-Ledard A, Prey S, Canal-Raffin M, Molimard M.
    Clin Chim Acta. 2017
  25. Antidepressant use and cognitive decline in community-dwelling elderly people - The Three-City Cohort.
    Carrière I, Norton J, Farré A, Wyart M, Tzourio C, Noize P, Pérès K, Fourrier-Réglat A, Ritchie K, Ancelin ML.
    BMC Med. 2017
  26. Absence of Decline of Kidney Function in Human Immunodeficiency Virus-Infected Patients Under Routine Clinical Management.
    Boucquemont J, Lawson-Ayayi S, Rigothier C, Bonnet F, Proust-Lima C, Neau D, Greib C, Miremont-Salamé G, Dabis F, Dupon M, Dauchy FA; for ANRS C03 Aquitaine Cohort Study Group.
    Nephron. 2017
  27. Hemodialysis does not impact axitinib exposure: clinical case of a patient with metastatic renal cell carcinoma.
    Thiery-Vuillemin A, Orillard E, Mouillet G, Calcagno F, Devillard N, Bouchet S, Royer B.
    Cancer Chemother Pharmacol. 2017
  28. Methods for safety signal detection in healthcare databases: a literature review.
    Arnaud M, Bégaud B, Thurin N, Moore N, Pariente A, Salvo F.
    Expert Opin Drug Saf. 2017
  29. The national healthcare system claims databases in France, SNIIRAM and EGB: Powerful tools for pharmacoepidemiology.
    Bezin J, Duong M, Lassalle R, Droz C, Pariente A, Blin P, Moore N.
    Pharmacoepidemiol Drug Saf. 2017
  30. Drug Interaction With Sunitinib and the Evidence of Therapeutic Drug Monitoring: A Case Report and Review of the Literature.
    Bertolaso P, Gross-Goupil M, Molimard M, Cochin V, Ravaud A, Daste A.
    Clin Genitourin Cancer. 2017
  31. Real-life patterns of use, safety and effectiveness of sunitinib in first-line therapy of metastatic renal cell carcinoma: the SANTORIN cohort study.
    Noize P, Grelaud A, Bay JO, Chevreau C, Gross-Goupil M, Culine S, Ferrière JM, Moulin F, Robinson P, Balestra A, Lamarque S, Bernard MA, Lassalle R, Rouyer M, Droz-Perroteau C, Moore N, Fourrier-Réglat A, Ravaud A.
    Pharmacoepidemiol Drug Saf. 2017
  32. Trends in the incidence of use of non-insulin glucose-lowering drugs between 2006 and 2013 in France.
    Arnaud M, Bezin J, Bégaud B, Pariente A, Salvo F.
    Fundam Clin Pharmacol. 2017
  33. Agreement between hospital discharge diagnosis codes and medical records to identify metastatic colorectal cancer and associated comorbidities in elderly patients.
    Gouverneur A, Dolatkhani D, Rouyer M, Grelaud A, Francis F, Gilleron V, Fourrier-Réglat A, Noize P.
    Rev Epidemiol Sante Publique. 2017
  34. False-positive results in pharmacoepidemiology and pharmacovigilance.
    Bezin J, Bosco-Levy P, Pariente A.
    Therapie. 2017
  35. Road traffic crash risk associated with prescription of hydroxyzine and other sedating H1-antihistamines: A responsibility and case-crossover study.
    Orriols L, Luxcey A, Contrand B, Bénard-Laribière A, Pariente A, Gadegbeku B, Lagarde E.
    Accid Anal Prev. 2017
  36. Impact of Medicine Withdrawal on Reporting of Adverse Events Involving Therapeutic Alternatives: A Study from the French Spontaneous Reporting Database.
    Pageot C, Bezin J, Smith A, Arnaud M, Salvo F, Haramburu F, Bégaud B, Pariente A; French Network of Pharmacovigilance Centres.
    Drug Saf. 2017
  37. A call to incorporate systems theory and human factors into the existing investigation of harm in clinical research involving healthcare products.
    Bégaud B, Daemen E, Dokas I, Edwards B, Fishbein JM, Greenberg HE, Hochberg A, Le Louet H, Lyngvig J, Mogles N, Owen K, Prendergast C, Rejzek M, Trantza S, Webb D, Whalen M, Whiteley S.
    Br J Clin Pharmacol. 2017
  38. Assessing drug causality: it is time to become European!
    Bégaud B.
    Pharmacol Res. 2017
  39. Trough dabrafenib plasma concentrations can predict occurrence of adverse events requiring dose reduction in metastatic melanoma.
    Rousset M, Dutriaux C, Bosco-Lévy P, Prey S, Pham-Ledard A, Dousset L, Gérard E, Bouchet S, Canal-Raffin M, Titier K, Molimard M.
    Clin Chim Acta. 2017
  40. Prescription medicine use by pedestrians and the risk of injurious road traffic crashes: A case-crossover study.
    Née M, Avalos M, Luxcey A, Contrand B, Salmi LR, Fourrier-Réglat A, Gadegbeku B, Lagarde E, Orriols L.
    PLoS Med. 2017
  41. Management and 3-month outcomes of isolated superficial vein thrombosis of the lower limb: A real-world cohort study.
    Blin P, Sevestre MA, Pouchain D, Gillet JL.
    Thromb Res. 2017
  42. Adherence with direct oral anticoagulants in nonvalvular atrial fibrillation new users and associated factors: a French nationwide cohort study.
    Maura G, Pariente A, Alla F, Billionnet C.
    Pharmacoepidemiol Drug Saf. 2017
  43. Prevalence and prescription patterns of oral glucocorticoids in adults: a retrospective cross-sectional and cohort analysis in France.
    Bénard-Laribière A, Pariente A, Pambrun E, Bégaud B, Fardet L, Noize P.
    BMJ Open. 2017
  44. National trends in use and costs of oral anticancer drugs in France: An 8-year population-based study.
    Bosco-Lévy P, de Boissieu P, Gouverneur A, Noize P, Molimard M, Fourrier-Réglat A, Bezin J.
    Pharmacoepidemiol Drug Saf. 2017
  45. Self-medication misuse in the Middle East: a systematic literature review.
    Khalifeh MM, Moore ND, Salameh PR.
    Pharmacol Res Perspect. 2017
  46. Development and validation of hospital information system-generated indicators of the appropriateness of oral anticoagulant prescriptions in hospitalised adults: the PACHA study protocol.
    Petit-Monéger A, Thiessard F, Jouhet V, Noize P, Berdaï D, Kret M, Sitta R, Salmi LR, Saillour-Glénisson F; PACHA research group.
    BMJ Open. 2017
  47. Impact of pioglitazone regulatory withdrawal on antidiabetic drug use and health in diabetic patients.
    Pariente A, Mansiaux Y, Jarné A, Salvo F, Pageot C, Bezin J, Smith A, Bégaud B.
    Eur J Clin Pharmacol. 2017
  48. Medications recommended for secondary prevention after first acute coronary syndrome: Effectiveness of treatment combinations in real-life setting.
    Bezin J, Klungel OH, Lassalle R, Dureau-Pournin C, Moore N, Pariente A.
    Clin Pharmacol Ther. 2017
  49. Phase I study of axitinib and everolimus in metastatic solid tumours and extension to metastatic renal cell carcinoma: Results of EVAX study.
    Ravaud A, Gomez-Roca C, Picat MQ, Digue L, Chevreau C, Gimbert A, Chauzit E, Sitta R, Cornelis F, Asselineau J, Aziza R, Daste A, Quemener C, Baud J, Bikfalvi A, Pedenon-Périchout D, Doussau A, Molimard M, Delord JP.
    Eur J Cancer. 2017
  50. Cirrhotic patients with portal hypertension-related bleeding and an indication for early-TIPS: a large multicentre audit with real-life results.
    Thabut D, Pauwels A, Carbonell N, Remy AJ, Nahon P, Causse X, Cervoni JP, Cadranel JF, Archambeaud I, Bramli S, Ehrhard F, Ah-Soune P, Rostain F, Pariente A, Vergniol J, Dupuychaffray JP, Pelletier AL, Skinazi F, Guillygomarc'h A, Vitte RL, Henrion J, Combet S, Rudler M, Bureau C; des Hépato-Gastroentérologues des Hôpitaux Généraux (ANGH).
    J Hepatol. 2017
  51. Recurrent herpetic keratitis despite antiviral prophylaxis: A virological and pharmacological study.
    Rousseau A, Boutolleau D, Titier K, Bourcier T, Chiquet C, Weber M, Colin J, Gueudry J, M'Garrech M, Bodaghi B, Burrel S, Agut H, Deback C; HEDGOF (Herpes Eye Disease Group of France), Labetoulle M.
    Antiviral Res. 2017
  52. Definition of indicators of the appropriateness of oral anticoagulant prescriptions in hospitalized adults: Literature review and consensus (PACHA study).
    Petit-Monéger A, Thiessard F, Noize P, Berdaï D, Jouhet V, Saillour-Glénisson F, Salmi LR; PACHA research group.
    Arch Cardiovasc Dis. 2017
  53. Risk of motor vehicle accidents related to sleepiness at the wheel: a systematic review and meta-analysis.
    Bioulac S, Micoulaud Franchi JA, Arnaud M, Sagaspe P, Moore N, Salvo F, Philip P.
    Sleep. 2017
  54. Comparative Safety of Targeted Therapies for Metastatic Colorectal Cancer between Elderly and Younger Patients: a Study Using the International Pharmacovigilance Database.
    Gouverneur A, Claraz P, Rousset M, Arnaud M, Fourrier-Réglat A, Pariente A, Aparicio T, Miremont-Salamé G, Noize P.
    Target Oncol. 2017
  55. Comparison of treatment persistence with dabigatran or rivaroxaban versus vitamin K antagonist oral anticoagulants in atrial fibrillation patients: a competing risk analysis in the French nationwide healthcare databases.
    Maura G, Billionnet C, Alla F, Gagne JJ, Pariente A.
    Pharmacotherapy. 2017
  56. Constituents and Antioxidant Activity of Bleeding Sap from Various Xinjiang Grapes.
    Le L, Umar A, Iburaim A, Moore N.
    Pharmacogn Mag. 2017
  57. Parachuting psychoactive substances: Pharmacokinetic clues for harm reduction.
    Daveluy A, Géniaux H, Baumevieille M, Létinier L, Matta MN, Lazès-Charmetant A, Haramburu F, Guéroult P.
    Addict Behav. 2017
  58. An Automated System Combining Safety Signal Detection and Prioritization from Healthcare Databases: A Pilot Study.
    Arnaud M, Bégaud B, Thiessard F, Jarrion Q, Bezin J, Pariente A, Salvo F.
    Drug Saf. 2017
  59. High throughput routine determination of 17 tyrosine kinase inhibitors by LC-MS/MS.
    Merienne C, Rousset M, Ducint D, Castaing N, Titier K, Molimard M, Bouchet S.
    J Pharm Biomed Anal. 2017
  60. Common variants in glucuronidation enzymes and membrane transporters as potential risk factors for colorectal cancer: a case control study.
    Falkowski S, Woillard JB, Postil D, Tubiana-Mathieu N, Terrebonne E, Pariente A, Smith D, Guimbaud R, Thalamas C, Rouguieg-Malki K, Marquet P, Picard N.
    BMC Cancer. 2017
  61. Demandes d’études post-inscription (EPI), suivi des patients en vie réelle : évolution de la place des bases de données.
    Berdaï D, Thomas-Delecourt F, Szwarcensztein K; table ronde recherche clinique et methodologie des Ateliers de Giens XXXIII, d'Andon A, Collignon C, Comet D, Déal C, Dervaux B, Gaudin AF, Lamarque-Garnier V, Lechat P, Marque S, Maugendre P, Méchin H, Moore N, Nachbaur G, Robain M, Roussel C, Tanti A, Thiessard F.
    Therapie. 2017
  62. Requests for post-registration studies (PRS), patients follow-up in actual practice: Changes in the role of databases.
    Berdaï D, Thomas-Delecourt F, Szwarcensztein K; Participants of Round Table Clinical research and methodology of Giens XXXIII.
    Therapie. 2017